ACMR Q1 2026 Earnings Strong EPS Beat Drives Stock Higher GXO Q1 2026 Earnings EPS Surges Past Estimates Amid Operational Efficiency Gains Fulcrum Therapeutics Q1 2026 Earnings Narrowed Loss Exceeds Analyst Expectations CRVS Q1 2026 Earnings EPS Slightly Misses Estimates Amid Continued Clinical Development IR Q1 2026 Earnings Modest EPS Beat Amid Slight Stock Decline OCCIO Q1 2026 Earnings Preferred Stock Reports Negative EPS of 076 Sharply Missing Estimates